NCT01340625View on ClinicalTrials.gov

Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Bioequivalence
Interventions
DRUG

Norethindrone/Ethinyl Estradiol

0.4 mg/35 mcg Chewable Tablets

DRUG

Ovcon® 35 Fe

0.4 mg/35 mcg Chewable Tablets

Trial Locations (1)

58104

PRACS Institute, Ltd., Fargo

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT01340625 - Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter